Who are we?
Our pursuit is progress for people everywhere. That’s why we take a closer look at things, ask questions and think ahead.
We’ve been around for 350 years, yet our majority owners are still the descendants of Friedrich Jacob Merck, the man who founded our company in Darmstadt, Germany in 1668.
Since then, we have become a truly global company, with around 51,000 employees in 66 countries working on breakthrough solutions and technologies. In 2017, we invested a total of € 2.1 billion in research and development.
We are Merck. The only exceptions are the United States and Canada. Here we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.
Drugs Disributed by Merck Serono Ltd
GnRH Agonist. Cetrorelix (as acetate) 0.25 mg/vial. PWDR. IN VIALS + SOLVENT IN
PREFILLED SYRINGES: Cetrotide 0.25: 1 x
7 complete kits. 1 vial S.C. 1 x dly at 24
hr intervals, morn. or even.
Prevent. prem. ovulat. in pts. undergoing
controlled ovar. stim., foll. by oocyte pickup
and assist. reproduct. techniques.
C/I/: Hypersens. to cetrorelix acetate,
extrinsic peptide hormones, mannitol.
Progestogen. Progesterone 8% w/w. SINGLE USE PREFILL. APPLICATS:
6, 15 x 1.125 g. Intravag. applic: Infert.
due to inad. lut. phase: 1 applic. dly
start. aft. document. ovulat. or arb. on
18th-21st day of cycle. In-vitro
fertilizat: Dly applic. cont. for 30 days if
lab. evidence of pregn.
Infertil. due to inad. lut. phase, in-vitro
fertilizat.
EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml. VIAL (I.V. infus.): 10 ml, 20 ml, 50 ml, 100
ml. Initial: 400 mg/m2, foll. by 1 x wkly
dose: 250 mg/m2.
Dosage must be individ. adjust.
according to pt. med. cond.
Tmt. of pts. with (EGFR)-expressing, RAS
wild-type metast. colorectal canc. incomb.
with irinotecan-based chemot., in 1st -line
in comb. with FOLFOX, as a single agent
in pts. who have failed oxaliplatinand
irinotecan- based ther. and whoare
intoler. to irinotecan. Tmt. of pts. With
squamous cell canc. of the head and neck
(SCCHN), in comb. with rad. ther.forlocal.
advanced dis., in comb. With platinumbased
chemo. for recur. and/or metast.
dis., as a single agent after fail. of
platinum-based chemo. for recur.and/or
metast. dis.
C/I: Severe hypersens, The comb. With
oxaliplatin-cont. chemot. is contraindic.
for pts. with mutant RAS metast.
colorectal canc. (mCRC) or for whom
RAS mCRC status is unknown.
Contraind. for concom. used chemot.
agents or rad. therapy must be
considered before init. of comb. tmt.
Thyroid Hormones. Levothyroxine Sodium 50 mcg, 100 mcg. SCORED TABS: 100 x 50 μg, 100 x 100 μg.
Start with low dose, increase grad.
every 2-4 wks until full replace. dose
reached.
Benign euthyroid goitre, prophylax.
relapse aft. surgery for euthyroid goitre,
hypothyroidism., supp. ther. thyroid
cancer, during anti-thyroid drug tmt.,
diagnost. use, See lit.
C/I: Hypersens., untreated adrenal and/
or pituitary insuffic., untreat.
thyrotoxicos., pregn., acute MI, acute
myocarditis, acute pancarditis, with
antithyroid agent. See lit.
Gonadotropin. Follitropin Alfa 600 IU/ml. PRE-FILLED PEN: Follitropin alfa 600 IU/
ml (eq. 44 μg/ml) 1 x 300 IU (eq. to 22
μg) + 5 needles; 1 x 450 IU (eq. to 33 μg)
+ 7 needles; 1 x 900 IU (eq. to 66 μg) +
14 needles. S.C. See lit.
Stim. follicular develop. and ovulat. in
WHO group II women, stim. multifollicular
develop. in pts. undergoing
ovulat. for assist. reproduct.
technologies.With concom. hCG ther.
stimulat. spermatogenes. in men who
have congen. or acquired
hypogonadotroph. hypogonadism.
Gonadotropin. Lutropin Alfa 75 IU/ml. VIALS (pwdr. + solv.): 1, 10. For S.C.
admin. See lit.
In assoc. with FSH to stim. follicular
develop. in women with severe LH and
FSH defic.
C/I: Hypersens. to gonadotrophins or to
any of the excip., ovarian, uterine or
mammary carcinoma, active untreat.
tumors hypothal., pituitary gland,
ovarian enlarge., cyst not due to
polycyst. ovarian dis., gyne.
hemorrhages of unknown origin.
